JP2012512887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512887A5 JP2012512887A5 JP2011542420A JP2011542420A JP2012512887A5 JP 2012512887 A5 JP2012512887 A5 JP 2012512887A5 JP 2011542420 A JP2011542420 A JP 2011542420A JP 2011542420 A JP2011542420 A JP 2011542420A JP 2012512887 A5 JP2012512887 A5 JP 2012512887A5
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- ylcarbamoyl
- thiazol
- tetrahydroquinolin
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 39
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 38
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004429 atom Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- -1 morpholino, pyrrolidinyl Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 15
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 15
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 15
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 230000005494 condensation Effects 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 10
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000004419 alkynylene group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 4
- 239000005973 Carvone Substances 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 2
- GUARKFCLDYLQOJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[4-(dimethylamino)phenoxy]propoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1OCCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O GUARKFCLDYLQOJ-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940081066 picolinic acid Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 claims 1
- SSVPVQYXJINXMD-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydroindol-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCC3=CC=2)=N1 SSVPVQYXJINXMD-UHFFFAOYSA-N 0.000 claims 1
- MPBQJXNTYAFDCG-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 MPBQJXNTYAFDCG-UHFFFAOYSA-N 0.000 claims 1
- ACWUWQFNFCECSG-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(3-phenoxypropyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1CCCOC1=CC=CC=C1 ACWUWQFNFCECSG-UHFFFAOYSA-N 0.000 claims 1
- ZHZAYMPWFBZMHS-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-ethoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OCC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 ZHZAYMPWFBZMHS-UHFFFAOYSA-N 0.000 claims 1
- GYMYCTAHQRHBRX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-fluorophenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1OC1=CC=C(F)C=C1 GYMYCTAHQRHBRX-UHFFFAOYSA-N 0.000 claims 1
- IUZOFLCDLUXADA-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 IUZOFLCDLUXADA-UHFFFAOYSA-N 0.000 claims 1
- BLYXYYLADZOEON-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-methoxyphenyl)-n,n-dimethyl-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C(=O)N(C)C)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 BLYXYYLADZOEON-UHFFFAOYSA-N 0.000 claims 1
- ATYICJLSTAZWCH-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-phenylphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1C(C=C1)=CC=C1C1=CC=CC=C1 ATYICJLSTAZWCH-UHFFFAOYSA-N 0.000 claims 1
- PHOMBWBRLPRDRL-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-propan-2-yloxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC(C)C)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 PHOMBWBRLPRDRL-UHFFFAOYSA-N 0.000 claims 1
- PVCRLFNDYPWXRE-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-(4-pyrazolo[3,4-d]pyrimidin-1-ylphenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C3=NC(=C(S3)OC=3C=CC(=CC=3)N3C4=NC=NC=C4C=N3)C(=O)O)=NC2=C1 PVCRLFNDYPWXRE-UHFFFAOYSA-N 0.000 claims 1
- DTCSCHOGNLBRFF-NTCAYCPXSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[(e)-2-phenylethenyl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1\C=C\C1=CC=CC=C1 DTCSCHOGNLBRFF-NTCAYCPXSA-N 0.000 claims 1
- JAUZXPWFDMIDMP-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-(4-tert-butylphenoxy)propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 JAUZXPWFDMIDMP-UHFFFAOYSA-N 0.000 claims 1
- GTWRWEWSFSCPBX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCCCC2=C(N=C(S2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 GTWRWEWSFSCPBX-UHFFFAOYSA-N 0.000 claims 1
- BFJVFGNQPLQUFT-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)S1 BFJVFGNQPLQUFT-UHFFFAOYSA-N 0.000 claims 1
- XBBJQSQPJIYQNM-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-phenoxy-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1OC1=CC=CC=C1 XBBJQSQPJIYQNM-UHFFFAOYSA-N 0.000 claims 1
- YVGIJURHOZQQNX-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-phenyl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)SC=1C1=CC=CC=C1 YVGIJURHOZQQNX-UHFFFAOYSA-N 0.000 claims 1
- HASSMSDDEAAJPW-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=N1 HASSMSDDEAAJPW-UHFFFAOYSA-N 0.000 claims 1
- ZZKMAEDLBJHEQI-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-fluorophenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=CC(F)=C1 ZZKMAEDLBJHEQI-UHFFFAOYSA-N 0.000 claims 1
- QUHHOHYGJVFKDL-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound COC1=CC=CC(C2=C(N=C(S2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)C(O)=O)=C1 QUHHOHYGJVFKDL-UHFFFAOYSA-N 0.000 claims 1
- SOLJRIFANYSREL-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(3-pyridin-4-ylsulfanylpropyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1CCCSC1=CC=NC=C1 SOLJRIFANYSREL-UHFFFAOYSA-N 0.000 claims 1
- LOHJTCRXLYLPCQ-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-carboxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=C(C(O)=O)C=C1 LOHJTCRXLYLPCQ-UHFFFAOYSA-N 0.000 claims 1
- ONXODEQOLDFBQK-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-fluorophenyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1C1=CC=C(F)C=C1 ONXODEQOLDFBQK-UHFFFAOYSA-N 0.000 claims 1
- LVKBROXLISEWPG-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-methoxyphenoxy)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 LVKBROXLISEWPG-UHFFFAOYSA-N 0.000 claims 1
- GMVXPHSJOARWRE-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-methoxyphenyl)-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 GMVXPHSJOARWRE-UHFFFAOYSA-N 0.000 claims 1
- SDMNMUQLECLURJ-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-(4-phenylbutyl)-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)SC=1CCCCC1=CC=CC=C1 SDMNMUQLECLURJ-UHFFFAOYSA-N 0.000 claims 1
- XSVMITITZADKSV-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-[3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 XSVMITITZADKSV-UHFFFAOYSA-N 0.000 claims 1
- HWSFZVVKRJNAAM-UHFFFAOYSA-N 2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-5-[methyl(2-phenoxyethyl)amino]-1,3-thiazole-4-carboxylic acid Chemical compound S1C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=NC(C(O)=O)=C1N(C)CCOC1=CC=CC=C1 HWSFZVVKRJNAAM-UHFFFAOYSA-N 0.000 claims 1
- BYMHFFYJCHILSC-UHFFFAOYSA-N 2-[4-(quinolin-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4N=C5C=CC=CC5=CC=4)CCOC3=CC=2)=N1 BYMHFFYJCHILSC-UHFFFAOYSA-N 0.000 claims 1
- QJSGRRAKWYNXIA-UHFFFAOYSA-N 3-(3-phenylpropoxy)-6-[4-(pyrazolo[1,5-a]pyridin-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC4=NN5C=CC=CC5=C4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 QJSGRRAKWYNXIA-UHFFFAOYSA-N 0.000 claims 1
- AYINEXHHTDRALS-UHFFFAOYSA-N 3-[2-(3-aminophenoxy)ethoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound NC1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 AYINEXHHTDRALS-UHFFFAOYSA-N 0.000 claims 1
- RCVLLTPEOVNERE-UHFFFAOYSA-N 3-[2-[4-(aminomethyl)phenoxy]ethoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O RCVLLTPEOVNERE-UHFFFAOYSA-N 0.000 claims 1
- LSULJKVPDWRHOH-UHFFFAOYSA-N 3-[3-(1,3-benzodioxol-5-yloxy)propoxy]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)OCCCOC=3C=C4OCOC4=CC=3)C(=O)O)=NC2=C1 LSULJKVPDWRHOH-UHFFFAOYSA-N 0.000 claims 1
- CGWQYFHTZRBUAD-UHFFFAOYSA-N 3-[3-[(3-aminophenoxy)methyl]phenyl]-6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound NC1=CC=CC(OCC=2C=C(C=CC=2)C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 CGWQYFHTZRBUAD-UHFFFAOYSA-N 0.000 claims 1
- VDKULKVSOILPLQ-UHFFFAOYSA-N 3-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]pyridine-2-carboxylic acid Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N1C2=C(OCC1)C=CC(=C2)C=1C(=NC=CC=1)C(=O)O VDKULKVSOILPLQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- XNAZSUQOXPFRCI-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-(1,3-thiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC=CN=4)CCCC3=CC=2)S1 XNAZSUQOXPFRCI-UHFFFAOYSA-N 0.000 claims 1
- NFBBOKMAQZIDEG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-[(4-methyl-1,3-thiazol-2-yl)carbamoyl]-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC=C(C)N=4)CCCC3=CC=2)S1 NFBBOKMAQZIDEG-UHFFFAOYSA-N 0.000 claims 1
- KSTDEFWREQYWLG-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-[1-[(5-methyl-1,3-thiazol-2-yl)carbamoyl]-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC(C)=CN=4)CCCC3=CC=2)S1 KSTDEFWREQYWLG-UHFFFAOYSA-N 0.000 claims 1
- CCIXRCPQCKVEBP-UHFFFAOYSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 CCIXRCPQCKVEBP-UHFFFAOYSA-N 0.000 claims 1
- GXQIXHPTOZPFNJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(1h-indol-5-yl)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)C=3C=C4C=CNC4=CC=3)C(=O)O)=NC2=C1 GXQIXHPTOZPFNJ-UHFFFAOYSA-N 0.000 claims 1
- YVYJHOMCXCHVPR-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-methyl-4-oxo-1h-quinazolin-6-yl)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C3=CC=C(C(=N3)C(O)=O)C3=CC=C4N=C(NC(=O)C4=C3)C)=NC2=C1 YVYJHOMCXCHVPR-UHFFFAOYSA-N 0.000 claims 1
- BVHQJPPKPSCFCT-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-methylpropoxy)pyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(OCC(C)C)=CC=C1C1=CC=C(CCCN2C(=O)NC=3SC4=CC=CC=C4N=3)C2=C1 BVHQJPPKPSCFCT-UHFFFAOYSA-N 0.000 claims 1
- CAOYRZRBLLJSBC-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-phenoxyethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCOC1=CC=CC=C1 CAOYRZRBLLJSBC-UHFFFAOYSA-N 0.000 claims 1
- OQQWYANTFMGUKE-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-phenylethynyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1C#CC1=CC=CC=C1 OQQWYANTFMGUKE-UHFFFAOYSA-N 0.000 claims 1
- NLQXXKDTSHGAQP-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-pyridin-2-ylethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCC1=CC=CC=N1 NLQXXKDTSHGAQP-UHFFFAOYSA-N 0.000 claims 1
- OUNKSAYPXCSZFA-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(2-pyridin-4-ylethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCC1=CC=NC=C1 OUNKSAYPXCSZFA-UHFFFAOYSA-N 0.000 claims 1
- XPXYZCVVFSWPNG-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-methylsulfonylphenyl)pyridine-2-carboxylic acid Chemical compound CS(=O)(=O)C1=CC=CC(C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 XPXYZCVVFSWPNG-UHFFFAOYSA-N 0.000 claims 1
- HJHOIRJAPDOTOL-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-morpholin-4-ylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCN1CCOCC1 HJHOIRJAPDOTOL-UHFFFAOYSA-N 0.000 claims 1
- ACSSINBYLJIAAG-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-phenylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 ACSSINBYLJIAAG-UHFFFAOYSA-N 0.000 claims 1
- KQDWYTVCGULVGO-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(3-quinolin-8-yloxypropoxy)pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)OCCCOC=3C4=NC=CC=C4C=CC=3)C(=O)O)=NC2=C1 KQDWYTVCGULVGO-UHFFFAOYSA-N 0.000 claims 1
- JNWWJUXWTIXBKQ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(4-tert-butylphenyl)pyridine-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O JNWWJUXWTIXBKQ-UHFFFAOYSA-N 0.000 claims 1
- UCGPCAWDOQTKSX-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(cyclobutylmethoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCC1CCC1 UCGPCAWDOQTKSX-UHFFFAOYSA-N 0.000 claims 1
- SUALKLTVTLZBAP-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[(4-phenylphenyl)methoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCC(C=C1)=CC=C1C1=CC=CC=C1 SUALKLTVTLZBAP-UHFFFAOYSA-N 0.000 claims 1
- CNWFABUNOZPXRG-JXMROGBWSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[(e)-2-(4-fluorophenyl)ethenyl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1\C=C\C1=CC=C(F)C=C1 CNWFABUNOZPXRG-JXMROGBWSA-N 0.000 claims 1
- QNLSEXFKDAEUHM-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-(2-oxopyrrolidin-1-yl)ethoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCN1CCCC1=O QNLSEXFKDAEUHM-UHFFFAOYSA-N 0.000 claims 1
- ZCJFOMBPZOLDAM-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[3-(dimethylamino)phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 ZCJFOMBPZOLDAM-UHFFFAOYSA-N 0.000 claims 1
- VMBDJGUXZKQXPY-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 VMBDJGUXZKQXPY-UHFFFAOYSA-N 0.000 claims 1
- VWDRTFKKWLAYQF-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]ethoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1OCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O VWDRTFKKWLAYQF-UHFFFAOYSA-N 0.000 claims 1
- IGRYCCZPZKOHII-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[2-[[4-(dimethylamino)phenyl]methylamino]ethoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1CNCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O IGRYCCZPZKOHII-UHFFFAOYSA-N 0.000 claims 1
- YLQNUEFFPHWWJJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-(4-chlorophenyl)propoxy]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1OCCCC1=CC=C(Cl)C=C1 YLQNUEFFPHWWJJ-UHFFFAOYSA-N 0.000 claims 1
- FVAHMCDFRIMIDJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[3-(dimethylamino)phenoxy]propoxy]pyridine-2-carboxylic acid Chemical compound CN(C)C1=CC=CC(OCCCOC=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 FVAHMCDFRIMIDJ-UHFFFAOYSA-N 0.000 claims 1
- NVPQUZOPZFEGPK-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[4-(dimethylamino)phenyl]propoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1CCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O NVPQUZOPZFEGPK-UHFFFAOYSA-N 0.000 claims 1
- UGYWSMFACSGFSA-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]phenoxy]methyl]phenyl]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(OCC=2C=C(C=CC=2)C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)=C1 UGYWSMFACSGFSA-UHFFFAOYSA-N 0.000 claims 1
- XOIHGIKDINPDRX-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]pyridine-2-carboxylic acid Chemical compound C1CN(C)CCN1C1=CC=C(C=2C(=NC(=CC=2)C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)C(O)=O)C=N1 XOIHGIKDINPDRX-UHFFFAOYSA-N 0.000 claims 1
- VOWYYLBWRUSDMW-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-butoxypyridine-2-carboxylic acid Chemical compound N1=C(C(O)=O)C(OCCCC)=CC=C1C1=CC=C(CCCN2C(=O)NC=3SC4=CC=CC=C4N=3)C2=C1 VOWYYLBWRUSDMW-UHFFFAOYSA-N 0.000 claims 1
- WYPAZEMYKBFKQE-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-hydroxypyridine-2-carboxylic acid Chemical compound C1=C(O)C(C(=O)O)=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=C1 WYPAZEMYKBFKQE-UHFFFAOYSA-N 0.000 claims 1
- HQDGISOEKNLNCW-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-naphthalen-2-ylpyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(NC(=O)N3CCCC4=CC=C(C=C43)C=3N=C(C(=CC=3)C=3C=C4C=CC=CC4=CC=3)C(=O)O)=NC2=C1 HQDGISOEKNLNCW-UHFFFAOYSA-N 0.000 claims 1
- WWSKHLBGFIOZBT-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-phenylpyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1C1=CC=CC=C1 WWSKHLBGFIOZBT-UHFFFAOYSA-N 0.000 claims 1
- XBXFJADFUJRUBK-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 XBXFJADFUJRUBK-UHFFFAOYSA-N 0.000 claims 1
- OYACQQIAQVEEMQ-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-2,3-dihydroquinoxalin-6-yl]-3-(3-phenoxypropoxy)pyridine-2-carboxylic acid Chemical compound C=1C=C2N(C)CCN(C(=O)NC=3SC4=CC=CC=C4N=3)C2=CC=1C(N=C1C(O)=O)=CC=C1OCCCOC1=CC=CC=C1 OYACQQIAQVEEMQ-UHFFFAOYSA-N 0.000 claims 1
- HRNHYKJWRGNWJS-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-2,3-dihydroquinoxalin-6-yl]pyridine-2-carboxylic acid Chemical compound C=1C=C2N(C)CCN(C(=O)NC=3SC4=CC=CC=C4N=3)C2=CC=1C1=CC=CC(C(O)=O)=N1 HRNHYKJWRGNWJS-UHFFFAOYSA-N 0.000 claims 1
- HMVBMFMZLAKSHW-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-phenoxypropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCOC1=CC=CC=C1 HMVBMFMZLAKSHW-UHFFFAOYSA-N 0.000 claims 1
- YKVDZNKXELHTAX-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-phenylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 YKVDZNKXELHTAX-UHFFFAOYSA-N 0.000 claims 1
- LWATZYLDPRGOCZ-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-3-(3-pyridin-4-ylpropoxy)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=NC=C1 LWATZYLDPRGOCZ-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010061825 Duodenal neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- NGTGDMNCIHYUOY-UHFFFAOYSA-N N-(1,3-benzothiazol-2-yl)-7-[5-(1-benzylpyrazol-4-yl)-6-methylpyridin-2-yl]-3,4-dihydro-2H-quinoline-1-carboxamide Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N1CCCC2=CC=C(C=C12)C1=CC=C(C(=N1)C)C=1C=NN(C=1)CC1=CC=CC=C1 NGTGDMNCIHYUOY-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- MPXONXSGCYHXEC-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)CCC2=CC=C(C=C2)F Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)CCC2=CC=C(C=C2)F MPXONXSGCYHXEC-UHFFFAOYSA-N 0.000 claims 1
- YEZWLRFUWBTVKJ-UHFFFAOYSA-N S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)OC2=CC=C(C=C2)N(C)C Chemical compound S1C(=NC2=C1C=CC=C2)NC(=O)N2CCCC1=CC=C(C=C21)C2=CC=C(C(=N2)C(=O)O)OC2=CC=C(C=C2)N(C)C YEZWLRFUWBTVKJ-UHFFFAOYSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010039 central nervous system leukemia Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000000312 duodenum cancer Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- KEBGAEIUKRGVKA-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-6-[6-(methylsulfonylcarbamoyl)-5-(3-phenylpropoxy)pyridin-2-yl]-2,3-dihydro-1,4-benzoxazine-4-carboxamide Chemical compound CS(=O)(=O)NC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)=CC=C1OCCCC1=CC=CC=C1 KEBGAEIUKRGVKA-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 201000002471 spleen cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13947908P | 2008-12-19 | 2008-12-19 | |
| US61/139,479 | 2008-12-19 | ||
| PCT/US2009/068400 WO2010080478A1 (en) | 2008-12-19 | 2009-12-17 | Compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512887A JP2012512887A (ja) | 2012-06-07 |
| JP2012512887A5 true JP2012512887A5 (https=) | 2014-10-09 |
| JP5683484B2 JP5683484B2 (ja) | 2015-03-11 |
Family
ID=42316717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542420A Active JP5683484B2 (ja) | 2008-12-19 | 2009-12-17 | 化合物と使用法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8114893B2 (https=) |
| EP (1) | EP2376085B1 (https=) |
| JP (1) | JP5683484B2 (https=) |
| KR (1) | KR101633532B1 (https=) |
| CN (1) | CN102325531B (https=) |
| AU (1) | AU2009335818A1 (https=) |
| BR (1) | BRPI0918337A2 (https=) |
| CA (1) | CA2747161C (https=) |
| CO (1) | CO6390110A2 (https=) |
| CR (1) | CR20110389A (https=) |
| DO (1) | DOP2011000198A (https=) |
| EC (1) | ECSP11011214A (https=) |
| ES (1) | ES2462715T3 (https=) |
| IL (1) | IL213547A0 (https=) |
| MX (1) | MX2011006514A (https=) |
| NZ (1) | NZ593536A (https=) |
| PE (1) | PE20120305A1 (https=) |
| RU (1) | RU2561109C2 (https=) |
| SG (1) | SG172266A1 (https=) |
| WO (1) | WO2010080478A1 (https=) |
| ZA (1) | ZA201104463B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| US8232273B2 (en) * | 2008-12-19 | 2012-07-31 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| RU2561109C2 (ru) * | 2008-12-19 | 2015-08-20 | Дженентек, Инк. | Соединения и способы применения |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10245255B2 (en) | 2011-02-14 | 2019-04-02 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| WO2014179734A1 (en) | 2013-05-02 | 2014-11-06 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| US10047075B2 (en) | 2014-01-24 | 2018-08-14 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| US9394303B2 (en) | 2014-04-04 | 2016-07-19 | The Regents Of The University Of Michigan | Small molecule inhibitors of MCL-1 and uses thereof |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| ES2726927T3 (es) * | 2014-07-08 | 2019-10-10 | Dow Agrosciences Llc | Proceso para la preparación de ácidos 3-hidroxipicolínicos |
| US10071087B2 (en) | 2014-07-22 | 2018-09-11 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
| EP3174890B1 (de) * | 2014-07-28 | 2019-03-13 | Merck Patent GmbH | Metallkomplexe |
| JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
| RU2726367C2 (ru) | 2016-03-28 | 2020-07-13 | Пресидж Байосайенсиз, Инк. | Фармацевтические комбинации для лечения злокачественной опухоли |
| JP6936498B2 (ja) | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN108251377B (zh) * | 2018-01-16 | 2021-08-27 | 内蒙古大学 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
| EP3743069B1 (en) | 2018-01-22 | 2025-08-06 | BioVentures, LLC | Bcl-2 proteins degraders for cancer treatment |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
| JP7612229B2 (ja) * | 2020-04-20 | 2025-01-14 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | ピラジン置換ニコチンアミドの固体形態ならびにその調製および使用 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| TW202345857A (zh) * | 2022-03-08 | 2023-12-01 | 美商昂科斯克塞爾醫療有限責任公司 | 他波司他之穩定調配物 |
| CN118974033A (zh) * | 2022-03-31 | 2024-11-15 | 百济神州有限公司 | Bcl-xL抑制剂 |
| CN120787162A (zh) | 2022-05-20 | 2025-10-14 | 诺华股份有限公司 | 抗肿瘤化合物的抗体-药物缀合物及其使用方法 |
| IL317102A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them |
| US20250339547A1 (en) | 2022-05-20 | 2025-11-06 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2332756A1 (fr) | 1975-11-26 | 1977-06-24 | Squibb & Sons Inc | Nouvelles 1, 4-benzoxazin-3(4h)-ones |
| DE19929785A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung |
| JP2003521543A (ja) * | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| WO2003020719A1 (en) | 2001-09-03 | 2003-03-13 | Takeda Chemical Industries, Ltd. | 1,3-benzothiazinone derivatives and use thereof |
| JP4403305B2 (ja) * | 2001-09-03 | 2010-01-27 | 武田薬品工業株式会社 | １，３−ベンゾチアジノン誘導体および用途 |
| SI1463563T1 (sl) | 2001-12-14 | 2009-06-30 | Alcon Inc | Superoksidni dizmutazni mimetiki za zdravljenje očesnih motenj in bolezni |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| DK2050749T3 (en) * | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF |
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| AU2007359392A1 (en) | 2007-09-27 | 2009-04-02 | The Walter And Eliza Hall Institute Of Medical Research | Benzothiazole compounds |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| US8232273B2 (en) * | 2008-12-19 | 2012-07-31 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| RU2561109C2 (ru) | 2008-12-19 | 2015-08-20 | Дженентек, Инк. | Соединения и способы применения |
-
2009
- 2009-12-17 RU RU2011129789/04A patent/RU2561109C2/ru active
- 2009-12-17 JP JP2011542420A patent/JP5683484B2/ja active Active
- 2009-12-17 NZ NZ593536A patent/NZ593536A/xx not_active IP Right Cessation
- 2009-12-17 EP EP09837907.6A patent/EP2376085B1/en active Active
- 2009-12-17 BR BRPI0918337A patent/BRPI0918337A2/pt not_active IP Right Cessation
- 2009-12-17 WO PCT/US2009/068400 patent/WO2010080478A1/en not_active Ceased
- 2009-12-17 PE PE2011001249A patent/PE20120305A1/es not_active Application Discontinuation
- 2009-12-17 ES ES09837907.6T patent/ES2462715T3/es active Active
- 2009-12-17 KR KR1020117016719A patent/KR101633532B1/ko not_active Expired - Fee Related
- 2009-12-17 US US12/641,063 patent/US8114893B2/en active Active
- 2009-12-17 CN CN200980157162.3A patent/CN102325531B/zh active Active
- 2009-12-17 MX MX2011006514A patent/MX2011006514A/es active IP Right Grant
- 2009-12-17 SG SG2011044922A patent/SG172266A1/en unknown
- 2009-12-17 CR CR20110389A patent/CR20110389A/es unknown
- 2009-12-17 CA CA2747161A patent/CA2747161C/en active Active
- 2009-12-17 AU AU2009335818A patent/AU2009335818A1/en not_active Abandoned
-
2011
- 2011-06-14 IL IL213547A patent/IL213547A0/en unknown
- 2011-06-15 ZA ZA2011/04463A patent/ZA201104463B/en unknown
- 2011-06-17 DO DO2011000198A patent/DOP2011000198A/es unknown
- 2011-07-01 CO CO11082793A patent/CO6390110A2/es active IP Right Grant
- 2011-07-18 EC EC2011011214A patent/ECSP11011214A/es unknown
-
2012
- 2012-01-10 US US13/347,364 patent/US8518970B2/en active Active
-
2013
- 2013-06-27 US US13/929,701 patent/US9067928B2/en active Active - Reinstated
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512887A5 (https=) | ||
| AU2016309833B2 (en) | Pharmaceutical composition and application replacing quinolone derivative, pharmaceutical acceptable salt, or stereoisomer | |
| AU2005205915B2 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
| EP4281078A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| ES2914099T3 (es) | Inhibidores novedosos de ULK1 y métodos de uso de los mismos | |
| ES2318158T3 (es) | Derivdos de diaril urea utiles para el tratamiento de enfermedades dependientes de la proteina quinasa. | |
| JP2021073269A (ja) | 細胞代謝過程の阻害剤 | |
| US20050222171A1 (en) | Organic compounds | |
| JP2011507854A5 (https=) | ||
| JP2011510995A5 (https=) | ||
| TW202122387A (zh) | Mta協同性之prmt5抑制劑 | |
| JP2019527725A (ja) | ４位置換アミノイソキノリン誘導体 | |
| RU2017112518A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| WO2002076954A1 (en) | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases | |
| AU2020307631B9 (en) | Casein kinase 1ε inhibitor, pharmaceutical composition and application thereof | |
| JP2010508324A (ja) | プロテインキナーゼモジュレーターとしての３−アミノカルボニル置換縮合ピラゾロ誘導体 | |
| EA024194B1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| CN101460500A (zh) | 作为激酶抑制剂的3-取代的N-(芳基-或杂芳基)-吡唑并[1,5-a]嘧啶 | |
| CN104936956A (zh) | 氨基取代的异噻唑 | |
| CN103068802B (zh) | 用于治疗增生性异常疾病的化合物 | |
| CN115260187A (zh) | 吡啶酮化合物及其用途 | |
| CN103214481B (zh) | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| EP3248979B1 (en) | Novel inhibitor of flt3 kinase and use thereof | |
| JP2006511498A5 (https=) | ||
| KR101937529B1 (ko) | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |